Advertisement
Canada markets closed
  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CAD/USD

    0.7319
    -0.0004 (-0.06%)
     
  • CRUDE OIL

    83.67
    +0.10 (+0.12%)
     
  • Bitcoin CAD

    87,297.31
    -1,439.20 (-1.62%)
     
  • CMC Crypto 200

    1,330.71
    -65.82 (-4.72%)
     
  • GOLD FUTURES

    2,351.40
    +8.90 (+0.38%)
     
  • RUSSELL 2000

    2,001.21
    +20.10 (+1.01%)
     
  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     
  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     
  • VOLATILITY

    15.01
    -0.36 (-2.34%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6836
    +0.0015 (+0.22%)
     

STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

NEW YORK, NY / ACCESSWIRE / April 16, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

  • Aegion Corp. (NASDAQ:AEGN) relating to its proposed acquisition by New Mountain Capital, LLC. Under the terms of the agreement, AEGN shareholders will receive $26.00 per share they own. Click here for more information: https://www.monteverdelaw.com/case/aegion-corp. It is free and there is no cost or obligation to you.

  • Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) relating to its proposed acquisition by AstraZeneca, PLC. Under the terms of the agreement, Alexion shareholders will receive 2.1243 shares of AstraZeneca and $60.00 in cash per share. Click here for more information: https://www.monteverdelaw.com/case/alexion-pharmaceuticals-inc. It is free and there is no cost or obligation to you.

  • GenMark Diagnostics, Inc. (NASDAQ:GNMK)relating to its proposed acquisition by Roche Holdings, Inc. Under the terms of the agreement, GNMK shareholders will receive $24.05 per share in cash. Click here for more information: http://monteverdelaw.com/case/genmark-diagnostics-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC
We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

ADVERTISEMENT

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2021 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE: Monteverde & Associates PC



View source version on accesswire.com:
https://www.accesswire.com/640873/STOCKHOLDER-ALERT-Monteverde-Associates-Continues-to-Investigate-the-Following-Merger